Identification of Circulating MicroRNAs As Diagnostic Biomarkers for Use in Multiple Myeloma

Overview

Journal Br J Cancer

Specialty Oncology

Date 2012 Nov 22

PMID 23169280

Citations 72

Authors

C I Jones

M V Zabolotskaya

A J King

H J S Stewart

G A Horne

T J Chevassut

S F Newbury

Affiliations

Soon will be listed here.

Abstract

Background: Multiple myeloma is a plasma cell disorder that is characterised by clonal proliferation of malignant plasma cells in the bone marrow, monoclonal paraprotein in the blood or urine and associated organ dysfunction. It accounts for approximately 1% of cancers and 13% of haematological cancers. Myeloma arises from an asymptomatic proliferation of monoclonal plasma cells termed monoclonal gammopathy of undetermined significance (MGUS).

Methods: MicroRNA expression profiling of serum samples was performed on three patient groups as well as normal controls. Validation of the nine microRNAs detected as promising biomarkers was carried out using TaqMan quantitative reverse transcription PCR. MicroRNA levels in serum were normalised using standard curves to determine the numbers of microRNAs per μl of serum.

Results: Three serum microRNAs, miR-720, miR-1308 and miR-1246, were found to have potential as diagnostic biomarkers in myeloma. Use of miR-720 and miR-1308 together provides a powerful diagnostic tool for distinguishing normal healthy controls, as well as patients with unrelated illnesses, from pre-cancerous myeloma and myeloma patients. In addition, the combination of miR-1246 and miR-1308 can distinguish MGUS from myeloma patients.

Conclusion: We have developed a biomarker signature using microRNAs extracted from serum, which has potential as a diagnostic and prognostic tool for multiple myeloma.

Citing Articles

Bone-organ axes: bidirectional crosstalk.

Deng A, Wang F, Wang S, Zhang Y, Bai L, Su J Mil Med Res. 2024; 11(1):37.

PMID: 38867330 PMC: 11167910. DOI: 10.1186/s40779-024-00540-9.

Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways.

Saadoune C, Nouadi B, Hamdaoui H, Chegdani F, Bennis F Bioinform Biol Insights. 2022; 16:11779322221115545.

PMID: 35958298 PMC: 9358573. DOI: 10.1177/11779322221115545.

The power of microRNAs as diagnostic and prognostic biomarkers in liquid biopsies.

Quirico L, Orso F Cancer Drug Resist. 2022; 3(2):117-139.

PMID: 35582611 PMC: 9090592. DOI: 10.20517/cdr.2019.103.

Non-Invasive microRNA Profiling in Saliva can Serve as a Biomarker of Alcohol Exposure and Its Effects in Humans.

Mead E, Boulghassoul-Pietrzykowska N, Wang Y, Anees O, Kinstlinger N, Lee M Front Genet. 2022; 12:804222.

PMID: 35126468 PMC: 8812725. DOI: 10.3389/fgene.2021.804222.

miRNAs in the Regulation of Cancer Immune Response: Effect of miRNAs on Cancer Immunotherapy.

Pottoo F, Iqubal A, Iqubal M, Salahuddin M, Rahman J, AlHajri N Cancers (Basel). 2021; 13(23).

PMID: 34885253 PMC: 8656569. DOI: 10.3390/cancers13236145.

References

Chikh A, Matin R, Senatore V, Hufbauer M, Lavery D, Raimondi C . iASPP/p63 autoregulatory feedback loop is required for the homeostasis of stratified epithelia. EMBO J. 2011; 30(20):4261-73. PMC: 3199390. DOI: 10.1038/emboj.2011.302. View

Walker B, Wardell C, Melchor L, Hulkki S, Potter N, Johnson D . Intraclonal heterogeneity and distinct molecular mechanisms characterize the development of t(4;14) and t(11;14) myeloma. Blood. 2012; 120(5):1077-86. DOI: 10.1182/blood-2012-03-412981. View

Reid G, Kirschner M, van Zandwijk N . Circulating microRNAs: Association with disease and potential use as biomarkers. Crit Rev Oncol Hematol. 2010; 80(2):193-208. DOI: 10.1016/j.critrevonc.2010.11.004. View

Jones C, Newbury S . Functions of microRNAs in Drosophila development. Biochem Soc Trans. 2010; 38(4):1137-43. DOI: 10.1042/BST0381137. View

Kyle R, Rajkumar S . Multiple myeloma. Blood. 2008; 111(6):2962-72. PMC: 2265446. DOI: 10.1182/blood-2007-10-078022. View

Pichiorri F, Suh S, Ladetto M, Kuehl M, Palumbo T, Drandi D . MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A. 2008; 105(35):12885-90. PMC: 2529070. DOI: 10.1073/pnas.0806202105. View

Faraoni I, Antonetti F, Cardone J, Bonmassar E . miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta. 2009; 1792(6):497-505. DOI: 10.1016/j.bbadis.2009.02.013. View

Lodes M, Caraballo M, Suciu D, Munro S, Kumar A, Anderson B . Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One. 2009; 4(7):e6229. PMC: 2704963. DOI: 10.1371/journal.pone.0006229. View

Zhu W, Qin W, Atasoy U, Sauter E . Circulating microRNAs in breast cancer and healthy subjects. BMC Res Notes. 2009; 2:89. PMC: 2694820. DOI: 10.1186/1756-0500-2-89. View

10.

BOREK E, Baliga B, GEHRKE C, Kuo C, BELMAN S, Troll W . High turnover rate of transfer RNA in tumor tissue. Cancer Res. 1977; 37(9):3362-6. View

11.

Neal C, Michael M, Pimlott L, Yong T, Li J, Gleadle J . Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant. 2011; 26(11):3794-802. DOI: 10.1093/ndt/gfr485. View

12.

Mitchell P, Parkin R, Kroh E, Fritz B, Wyman S, Pogosova-Agadjanyan E . Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A. 2008; 105(30):10513-8. PMC: 2492472. DOI: 10.1073/pnas.0804549105. View

13.

Kyle R, Remstein E, Therneau T, Dispenzieri A, Kurtin P, Hodnefield J . Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N Engl J Med. 2007; 356(25):2582-90. DOI: 10.1056/NEJMoa070389. View

14.

Zen K, Zhang C . Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med Res Rev. 2012; 32(2):326-48. DOI: 10.1002/med.20215. View

15.

Chen X, Liang H, Zhang J, Zen K, Zhang C . Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol. 2012; 22(3):125-32. DOI: 10.1016/j.tcb.2011.12.001. View

16.

Kong Y, Ferland-McCollough D, Jackson T, Bushell M . microRNAs in cancer management. Lancet Oncol. 2012; 13(6):e249-58. DOI: 10.1016/S1470-2045(12)70073-6. View

17.

Roccaro A, Sacco A, Thompson B, Leleu X, Azab A, Azab F . MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009; 113(26):6669-80. PMC: 2710922. DOI: 10.1182/blood-2009-01-198408. View

18.

Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S . Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 2009; 114(25):e20-6. DOI: 10.1182/blood-2009-08-237495. View

19.

Heneghan H, Miller N, Kelly R, Newell J, Kerin M . Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist. 2010; 15(7):673-82. PMC: 3228012. DOI: 10.1634/theoncologist.2010-0103. View

20.

Roth C, Rack B, Muller V, Janni W, Pantel K, Schwarzenbach H . Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res. 2010; 12(6):R90. PMC: 3046429. DOI: 10.1186/bcr2766. View